Every 8-K that Xencor, Inc. (XNCR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow XNCR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XNCR filings page.
Xencor reported second-quarter 2026 revenue of $51.2 million and a net loss of $21.7 million (–$0.29 per share), compared with $43.6 million revenue and a $30.8 million loss a year earlier. Cash, cash equivalents and marketable debt securities were $486.4 million at June 30, 2026.
Revenue reflected milestone income from Zenas BioPharma and royalties from Alexion and Incyte, including $27.6 million of U.S. Ultomiris royalties recognized after resolving a dispute with Alexion. Under a new settlement, Xencor will receive a total of $105 million, with the remaining $77.4 million to be recognized in the third quarter of 2026.
Management expects to end 2026 with $420–$440 million in cash and to fund operations through 2028. The pipeline advanced with multiple Phase 1 and 2 studies, FDA Fast Track designation for XmAb541 in germ cell tumors, and an oral ESMO 2026 presentation of Phase 1 data for the renal cancer candidate XmAb819.
Xencor, Inc. entered into a Settlement Agreement with Alexion Pharma International Operations Limited to resolve a commercial dispute over U.S. royalties on Ultomiris (ravulizumab-cwvz). Under the agreement, Xencor will receive $105 million in two equal cash payments of $52.5 million.
The first payment is anticipated in August 2026, and the second is due within 14 days after the one-year anniversary of the Settlement Agreement. In exchange, Alexion will have no further obligation to pay royalties on U.S. sales of Ultomiris, while royalties on ex-U.S. sales continue unchanged. Based on current operating plans, Xencor expects to have cash resources to fund research and development programs and operations through 2028.
Xencor, Inc. held its 2026 Annual Meeting of Stockholders, with 63,939,410 common shares present or represented by proxy, equal to approximately 86.26% of the 74,127,372 shares outstanding and entitled to vote as of April 17, 2026.
Stockholders elected nine directors to serve until the 2027 Annual Meeting and ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. They also approved an amendment and restatement of the 2023 Equity Incentive Plan, increasing authorized shares reserved for issuance by 4,000,000 shares, and approved on an advisory, non-binding basis the compensation of the company’s named executive officers.
Xencor, Inc. reported significantly weaker first-quarter 2026 results. Revenue was $4.5 million, down sharply from $32.7 million a year earlier, reflecting lower collaboration and royalty income and a one-time $6.6 million reduction for disputed Alexion royalties.
The company recorded a net loss attributable to Xencor of $128.9 million, or $(1.71) per share, compared with a $48.4 million loss, or $(0.66) per share, in 2025, driven by higher R&D spending and $50.8 million of other expense from unrealized losses on an equity security. Xencor ended March 31, 2026 with $541.8 million in cash, cash equivalents and marketable debt securities and expects to finish 2026 with $380–$400 million, providing cash runway into mid-2028 while advancing multiple oncology and autoimmune programs.
Xencor, Inc. reported final Phase 1 results for XmAb942, an extended half-life anti‑TL1A antibody for inflammatory bowel disease, and outlined progress across its TL1A portfolio. In healthy participants, XmAb942 was well tolerated, with an estimated terminal half‑life of 74.1 days and no serious or severe adverse events.
Quantitative pharmacology modeling suggests XmAb942 could achieve greater than 99% TL1A inhibition in 86% of patients during 12‑week induction and greater than 90% inhibition in 90% of patients on 12‑weekly maintenance dosing in the ongoing ~220‑patient Phase 2b XENITH‑UC ulcerative colitis study. Xencor also highlighted XmAb412, a TL1A x IL23p19 bispecific using its XenLock format, which showed very high in vitro potency, non‑human primate half‑life over 20 days and is planned to enter a first‑in‑human healthy volunteer study in the third quarter of 2026, with interim XmAb412 data and XENITH‑UC readouts expected through 2027.
Xencor, Inc. adopted a new Executive Severance Policy covering its currently serving named executive officers other than the Chief Executive Officer. Eligible executives must sign a participation agreement to receive benefits.
If Xencor terminates an eligible executive without Cause or the executive resigns for Good Reason outside a change in control period and the executive signs a release, the executive is entitled to a lump-sum payment equal to 15 months of base salary plus up to 15 months of paid COBRA health coverage.
If such a termination occurs during a defined change in control period, the executive also receives bonus compensation equal to 15 months of target bonus, a prorated annual bonus, and accelerated vesting of all outstanding, unvested stock options and equity awards, subject to a release of claims.
Xencor, Inc. reported that Genentech, Inc. and F. Hoffmann-La Roche Ltd are terminating their Amended and Restated Collaboration and License Agreement covering efbalropendekin alfa. Genentech elected to end the agreement for convenience, with termination effective September 4, 2026.
Efbalropendekin alfa, an engineered cytokine-Fc fusion protein, was the sole active collaboration product under the agreement. Roche had already removed it from its development pipeline in connection with its 2024 financial results, and Xencor had earlier opted out of co-development and ceased cost-sharing activities in the first half of 2024.
Xencor, Inc. disclosed that Alexion Pharmaceuticals, the licensee for Ultomiris, has taken the position that it does not owe any additional royalties on U.S. sales of Ultomiris and does not intend to make future U.S. royalty payments under their Option and License Agreement. Alexion told Xencor it will continue paying royalties on sales outside the United States, and Xencor strongly disagrees with Alexion’s position and is evaluating its options.
Xencor had previously expected an estimated additional $100–$120 million in low single-digit U.S. Ultomiris royalties through 2028 based on a recently issued U.S. patent. Despite this potential loss of anticipated revenue, Xencor now expects to end 2026 with $380–$400 million in cash, cash equivalents and marketable debt securities and believes this will fund its research and operations into mid‑2028.
Xencor reported 2025 results showing higher revenue and a much smaller loss while advancing a broad pipeline. Full-year revenue rose to $125.6 million from $110.5 million, driven mainly by Alexion and Incyte license revenue. Net loss attributable to Xencor narrowed to $91.9 million, or $(1.24) per share, from $232.6 million, or $(3.58) per share.
Cash, cash equivalents and marketable debt securities totaled $610.8 million as of December 31, 2025, and the company expects to end 2026 with $400–$430 million, funding operations through 2028. Xencor highlighted multiple clinical programs, including Phase 1 dose expansion for lead oncology asset XmAb819 and progress across its TL1A inflammatory bowel disease portfolio, with several data presentations and potential pivotal-study decisions planned in 2026–2027.
The company also noted a U.S. patent term extension for its Xtend Fc domain used in Ultomiris, and estimates potential royalty revenue of $100–$120 million in aggregate over the extended period through 2028.
Xencor, Inc. reports a preliminary estimate that its cash, cash equivalents and marketable debt securities totaled approximately $611 million as of December 31, 2025, compared with $706.7 million as of December 31, 2024. The company states that, based on its current operating plans, this cash position is expected to fund its research and development programs and operations through 2028. These figures are preliminary, unaudited and may change when year-end closing and auditing procedures are completed.
Xencor, Inc. furnished a Form 8-K announcing financial results for the third quarter ended September 30, 2025, via a press release attached as Exhibit 99.1.
The company stated this information is being furnished and shall not be deemed to be filed under the Exchange Act. The filing also includes the cover page interactive data file.
Xencor, Inc. furnished an update under Regulation FD. The company held a conference call on October 24, 2025 to discuss initial results from the ongoing Phase 1 dose-escalation study of XmAb819 (ENPP3 x CD3), early data from the ongoing Phase 1 dose-escalation study of XmAb541 (CLDN6 x CD3), and associated near-term clinical timelines.
Supporting materials were furnished, not filed, including a presentation (Exhibit 99.1) and a press release (Exhibit 99.2). The presentation is stated to be current as of April 29, 2025. The company noted that these materials are incorporated by reference as furnished under Item 7.01 and are not deemed filed for Section 18 purposes.